(Reuters) - Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available ...

After she was diagnosed at age 48 with Type 1 diabetes, Stacey Silverman muddled through her days with high blood sugar, fatigue and splitting headaches. Taking a long-acting form of insulin called ...

Levemir, one of the three types of long-acting basal insulins, is evacuating the U.S. market, and diabetes patient advocates told USA Today they’re worried about using a new medication after nearly ...

Novo Nordisk (NVO) is reportedly set to meet with U.S. Senate aides on Tuesday to discuss why the drugmaker is discontinuing marketing its long-acting insulin Levemir in the U.S. The Danish drugmaker ...

As a special education teacher living with Type 1 diabetes in Crawfordsville, I’ve relied on insulin to manage my condition since my diagnosis in 2011. Despite my engagement as an #insulin4all ...

A year ago, when Novo Nordisk announced it would cut the price of multiple insulin products by up to 75%, President Biden, lawmakers, and patient groups all counted the move as a win. But several ...

Novo Nordisk maintains that patients have ample time to transition to other options. Novo Nordisk, Eli Lilly, and Sanofi control 100% of the insulin market in the U.S Get two weeks of free access to ...

Novo Nordisk will meet with the aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren. In April, the lawmakers wrote to the company expressing alarm at its decision, announced in ...

LONDON (Reuters) - Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk's long-lasting insulin Levemir than on shorter-acting products, researchers said on ...

COPENHAGEN, Oct 22 (Reuters) - Denmark's Novo Nordisk , the world's biggest maker of insulin, said on Monday Japanese health authorities have approved it long-acting insulin Levemir for use in type 1 ...